This inventor holds 1 USPTO granted patent. Top assignee: National Research Council of Canada. Active years: 1999.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1999
Title: The Innovations of Robert Menard
Introduction
Robert Menard is a notable inventor based in St. Laurent, Canada. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that exhibit therapeutic potential for various diseases. His work is characterized by a focus on cysteine protease inhibitors, which play a crucial role in treating conditions such as muscular dystrophy and cancer metastasis.
Latest Patents
Menard holds a patent for his invention titled "6-substituted amino-4-oxa-1-azabicyclo-3,2,0-heptan-7-one derivatives." This patent describes novel compounds that demonstrate excellent cysteine protease inhibitory activity. These compounds may be utilized in the treatment of several diseases, including arthritis, myocardial infarction, Alzheimer's disease, bacterial infections, the common cold, osteoporosis, and cancer metastasis. He has been granted 1 patent for this innovative work.
Career Highlights
Menard is affiliated with the National Research Council of Canada, where he has been able to leverage his expertise in medicinal chemistry. His research has contributed to advancements in drug development and has the potential to impact the treatment landscape for various debilitating diseases.
Collaborations
Throughout his career, Menard has collaborated with esteemed colleagues, including Nian E Zhou and Enrico O Purisima. These partnerships have fostered a collaborative environment that enhances the research and development of innovative pharmaceutical solutions.
Conclusion
Robert Menard's contributions to the field of pharmaceuticals through his innovative patents and collaborative efforts highlight his commitment to advancing medical science. His work continues to pave the way for new treatments that can improve the quality of life for many individuals.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile